Patient Resources

What are clinical trials and who can participate?

Learn more

Seattle Genetics is focused on generating clinical data that support the utility of our innovative product candidates in improving the treatment and outcomes for patients with cancer. We post clinical trial protocol information for our studies on the National Institutes of Health (NIH) Clinical Trials website at www.clinicaltrials.gov.

For information on other trials sponsored by investigators, search clinicaltrials.gov

Moving from promise to practice in the clinic

Trials by Therapeutic Areas

Hodgkin Lymphoma

  • Phase 3 ECHELON-1 trial of brentuximab vedotin plus AVD versus ABVD for frontline treatment of advanced classical Hodgkin lymphoma. Study #C25003 is currently recruiting participants.learn more
  • Phase 2 trial for frontline treatment of Hodgkin lymphoma in patients age 60 and above evaluating brentuximab vedotin as a single agent and in combination with other agents. Study #SGN35-015 is currently recruiting participants.learn more

Non-Hodgkin Lymphoma

  • Phase 3 ALCANZA trial evaluating brentuximab vedotin versus investigator's choice of methotrexate or bexarotene for relapsed CD30-positive cutaneous T-cell lymphoma (primary cutaneous anaplastic large cell lymphoma, mycosis fungoides). Study #C25001 is currently recruiting participants. learn more
  • Phase 3 ECHELON-2 trial for frontline treatment of mature T-cell lymphomas comparing brentuximab vedotin plus CHP with the standard-of-care CHOP. Study #SGN35-014 is currently recruiting participants.learn more
  • Phase 2 study for frontline treatment of diffuse large B-cell lymphoma evaluating brentuximab vedotin in combination with RCHOP or RCHP. Study #SGN35-017 is currently recruiting participants.learn more
  • Phase 1 trial of SGN-CD19A for relapsed highly aggressive lymphomas.Study #SGN19A-001 is currently recruiting participants.learn more
  • Phase 1 trial of SGN-CD19A for relapsed or refractory B-lineage non-Hodgkin lymphoma. Study #SGN19A-002 is currently recruiting participants.learn more
  • Phase 1 trial of SGN-CD70A for relapsed or refractory non-Hodgkin lymphoma. Study #SGN70A-001 is currently recruiting participants.learn more

Leukemia & Other Blood Cancers

  • Phase 1 trial of SGN-CD19A for relapsed B-lineage acute lymphoblastic leukemia (also called acute lymphocytic leukemia). Study #SGN19A-001 is currently recruiting participants.learn more
  • Phase 1 trial for relapsed acute myeloid leukemia evaluating SGN-CD33A as a single agent. Study #SGN33A-001 is currently recruiting participants.learn more
  • Phase 1b trial for acute myeloid leukemia evaluating SGN-CD33A given in combination with standard treatment or by itself for maintenance treatment. Study #SGN33A-002 is currently recruiting participants.learn more

Solid Tumors

  • Phase 1 trial of SGN-LIV1A for LIV-1-positive metastatic breast cancer. Study #SGNLVA-001 is currently recruiting participants.learn more
  • Phase 1 trial of SGN-CD70A for relapsed or refractory renal cell carcinoma. Study #SGN70A-001 is currently recruiting participants.learn more
  • Phase 1 trial of ASG-22ME for malignant solid tumors that express Nectin-4. Enrollment in study #AGS-22M6E-11-1 is complete.learn more
  • Phase 1 trial for relapsed bladder cancer evaluating of ASG-15ME as a single agent. Study #AGS15E-13-1 is currently recruiting participants.learn more
  • Phase 1 trial of SEA-CD40 for advanced malignancies. Study #SGNS40-001 is currently recruiting participants.learn more

Trials by Program

Brentuximab Vedotin

  • Phase 3 ECHELON-1 trial of brentuximab vedotin plus AVD versus ABVD for frontline treatment of advanced classical Hodgkin lymphoma. Study #C25003 is currently recruiting participants.learn more
  • Phase 3 ECHELON-2 trial of frontline treatment for mature T-cell lymphomas comparing brentuximab vedotin plus CHP with the standard-of-care CHOP. Study #SGN35-014 is currently recruiting participants.learn more
  • Phase 3 ALCANZA trial evaluating brentuximab vedotin versus investigator's choice of methotrexate or bexarotene for relapsed CD30-positive cutaneous T-cell lymphoma (primary cutaneous anaplastic large cell lymphoma, mycosis fungoides). Study #C25001 is currently recruiting participants.learn more
  • Phase 2 study for frontline treatment of diffuse large B-cell lymphoma evaluating brentuximab vedotin in combination with RCHOP or RCHP. Study #SGN35-017 is currently recruiting participants.learn more
  • Phase 2 trial for frontline treatment of Hodgkin lymphoma in patients age 60 and above evaluating brentuximab vedotin as a single agent and in combination with other agents. Study #SGN35-015 is currently recruiting participants.learn more

SGN-CD19A

  • Phase 1 trial for relapsed B-lineage acute lymphoblastic leukemia (also called acute lymphocytic leukemia) and highly aggressive lymphomas. Study #SGN19A-001 is currently recruiting participants..learn more
  • Phase 1 trial for relapsed or refractory B-lineage non-Hodgkin lymphoma. Study #SGN19A-002 is currently recruiting participants.learn more

SGN-CD33A

  • Phase 1 trial for acute myeloid leukemia evaluating SGN-CD33A as a single agent. Study #SGN33A-001 is currently recruiting participants.learn more
  • Phase 1b trial for acute myeloid leukemia evaluating SGN-CD33A given in combination with standard treatment or by itself for maintenance treatment. Study #SGN33A-002 is currently recruiting participants.learn more

SGN-LIV1A

  • Phase 1 trial for LIV-1-positive metastatic breast cancer. Study #SGNLVA-001 is currently recruiting participants.learn more

SGN-CD70A

  • Phase 1 trial for relapsed or refractory renal cell carcinoma or non-Hodgkin lymphoma. Study #SGN70A-001 is currently recruiting participants.learn more

ASG-22ME

  • Phase 1 trial for malignant solid tumors that express Nectin-4. Enrollment in study #AGS-22M6E-11-1 is complete.learn more

ASG-15ME

  • Phase 1 trial for relapsed bladder cancer evaluating ASG-15ME as a single agent. Study #AGS15E-13-1 is currently recruiting participants.learn more

SEA-CD40

  • Phase 1 trial for advanced malignancies. Study #SGNS40-001 is currently recruiting participants..learn more

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave SeattleGenetics.com?

No, return to SeattleGenetics.com

Yes, leave SeattleGenetics.com